Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba

• Status: Unknown status
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Pityriasis alba (PA) is a common benign skin disorder, that usually affects children and adolescents of darker phototypes. A history of atopic dermatitis is a well-known risk factor, and PA may be a minor manifestation of atopic dermatitis, although it can occur in nonatopic individuals as well. The objective is to evaluate the effect of topical pimecrolimus in the treatment of treatment of PA

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St Joseph University, Beirut, Lebanon
• Treatments: Pimecrolimus; Sunscreening Agents

Criteria

Inclusion Criteria:

• Pityriasis alba Patients confirmed by a board certified dermatologist

• Age over 2 years

• Written informed consent signed by the patients or the legal guardians of patients younger than 18 years in the native language (Arabic)

Exclusion Criteria:

• Other concomitant dermatosis (except atopic dermatitis)

• Use of topical steroids, or topical agents other than emollients and sunscreen, in the last 4 weeks

• Known allergy to pimecrolimus

• Pregnant and nursing women